NASDAQ:AGEN Agenus (AGEN) Stock Forecast, Price & News $1.59 +0.03 (+1.92%) (As of 02:51 PM ET) Add Compare Share Share Today's Range$1.49▼$1.6350-Day Range$1.31▼$1.8052-Week Range$1.25▼$3.37Volume2.08 million shsAverage Volume4.76 million shsMarket Capitalization$554.72 millionP/E RatioN/ADividend YieldN/APrice Target$7.33 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Agenus MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside359.2% Upside$7.33 Price TargetShort InterestBearish5.74% of Shares Sold ShortDividend StrengthN/ASustainability-0.93Upright™ Environmental ScoreNews Sentiment0.35Based on 3 Articles This WeekInsider TradingAcquiring Shares$267,492 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.81) to ($0.74) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.27 out of 5 starsMedical Sector655th out of 1,980 stocksBiological Products, Except Diagnostic Industry89th out of 330 stocks 3.5 Analyst's Opinion Consensus RatingAgenus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.33, Agenus has a forecasted upside of 359.2% from its current price of $1.60.Amount of Analyst CoverageAgenus has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.74% of the outstanding shares of Agenus have been sold short.Short Interest Ratio / Days to CoverAgenus has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Agenus has recently increased by 2.46%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAgenus does not currently pay a dividend.Dividend GrowthAgenus does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAgenus has received a 72.61% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Agenus is -0.93. Previous Next 1.9 News and Social Media Coverage News SentimentAgenus has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Agenus this week, compared to 4 articles on an average week.Search InterestOnly 9 people have searched for AGEN on MarketBeat in the last 30 days. This is a decrease of -31% compared to the previous 30 days.MarketBeat Follows8 people have added Agenus to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Agenus insiders have bought more of their company's stock than they have sold. Specifically, they have bought $267,492.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 4.80% of the stock of Agenus is held by insiders.Percentage Held by Institutions53.81% of the stock of Agenus is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Agenus are expected to grow in the coming year, from ($0.81) to ($0.74) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Agenus is -1.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Agenus is -1.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Agenus (NASDAQ:AGEN) StockAgenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.Read More Receive AGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Agenus and its competitors with MarketBeat's FREE daily newsletter. Email Address AGEN Stock News HeadlinesMay 27, 2023 | msn.comEF Hutton Reiterates Agenus (AGEN) Buy RecommendationMay 25, 2023 | finance.yahoo.comAgenus to Participate in Jefferies Healthcare ConferenceJune 1, 2023 | Edge On The Street (Ad)Graphite Shortage Could Derail the $7 Trillion EV TransitionGraphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.May 21, 2023 | americanbankingnews.comAgenus Inc. (NASDAQ:AGEN) Receives $7.33 Consensus Price Target from BrokeragesMay 20, 2023 | americanbankingnews.comAgenus (NASDAQ:AGEN) Coverage Initiated at StockNews.comMay 15, 2023 | americanbankingnews.comAgenus Inc. (NASDAQ:AGEN) Sees Large Decline in Short InterestMay 14, 2023 | americanbankingnews.comAgenus Inc. (NASDAQ:AGEN) Major Shareholder Agenus Inc Acquires 22,065 SharesMay 14, 2023 | americanbankingnews.comResearch Analysts Set Expectations for Agenus Inc.'s FY2023 Earnings (NASDAQ:AGEN)June 1, 2023 | Edge On The Street (Ad)ChatGPT Is Already "Old School"As good as ChatGPT is at writing content, it still doesn't understand what it's saying. But a new AI technology breakthrough will understand and process information like a human. One young company is leading the way.May 14, 2023 | americanbankingnews.comB. Riley Analysts Boost Earnings Estimates for Agenus Inc. (NASDAQ:AGEN)May 13, 2023 | americanbankingnews.comFY2027 Earnings Forecast for Agenus Inc. (NASDAQ:AGEN) Issued By William BlairMay 11, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Buy Rating on Agenus (AGEN)May 10, 2023 | finance.yahoo.comBroker Revenue Forecasts For Agenus Inc. (NASDAQ:AGEN) Are Surging HigherMay 9, 2023 | finance.yahoo.comAgenus (AGEN) Q1 2023 Earnings Call TranscriptMay 9, 2023 | finance.yahoo.comAgenus (AGEN) Reports Q1 Loss, Lags Revenue EstimatesMay 9, 2023 | finance.yahoo.comAgenus Provides Corporate Update and First Quarter 2023 Financial ResultsMay 8, 2023 | americanbankingnews.comInsider Buying: Agenus Inc. (NASDAQ:AGEN) Major Shareholder Purchases $95,190.00 in StockMay 6, 2023 | marketwatch.com2030 Vision: Therapeutic Vaccines Market Value to Hit New HeightsMay 3, 2023 | finance.yahoo.comAgenus Selected for Late-Breaking Oral Presentation at ESMO-GIApril 27, 2023 | americanbankingnews.comAgenus (NASDAQ:AGEN) Shares Up 4%April 26, 2023 | finance.yahoo.comAgenus to Present at the American Society of Clinical Oncology 2023 Annual MeetingApril 26, 2023 | americanbankingnews.comAnalysts Set Agenus Inc. (NASDAQ:AGEN) Price Target at $7.33April 25, 2023 | finance.yahoo.comAgenus to Provide Corporate Update and First Quarter 2023 Financial ReportApril 24, 2023 | finance.yahoo.comAgenus to Participate in May Investor ConferencesApril 22, 2023 | markets.businessinsider.comB.Riley Financial Sticks to Its Buy Rating for Agenus (AGEN)April 19, 2023 | americanbankingnews.comShort Interest in Agenus Inc. (NASDAQ:AGEN) Grows By 16.4%April 18, 2023 | thestreet.comJim Cramer on Agenus (AGEN) Stock: ‘I Still Like It’See More Headlines AGEN Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AGEN Company Calendar Last Earnings3/14/2023Today6/01/2023Next Earnings (Estimated)8/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:AGEN CUSIP00847G70 CIK1098972 Webagenusbio.com Phone(781) 674-4400Fax781-674-4200Employees441Year FoundedN/APrice Target and Rating Average Stock Price Forecast$7.33 High Stock Price Forecast$8.30 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+359.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-220,070,000.00 Net Margins-264.19% Pretax Margin-264.19% Return on Equity-1,159.04% Return on Assets-58.65% Debt Debt-to-Equity RatioN/A Current Ratio1.08 Quick Ratio1.08 Sales & Book Value Annual Sales$98.02 million Price / Sales5.68 Cash FlowN/A Price / Cash FlowN/A Book Value($0.15) per share Price / Book-10.63Miscellaneous Outstanding Shares348,880,000Free Float332,130,000Market Cap$556.46 million OptionableOptionable Beta1.43 Key ExecutivesGaro H. ArmenChairman & Chief Executive OfficerChristine M. KlaskinChief Financial & Accounting Officer, VP-FinanceSteven O’DayChief Medical OfficerCraig WinterChief Information OfficerAlfred DadsonChief Manufacturing OfficerKey CompetitorsNovavaxNASDAQ:NVAXSangamo TherapeuticsNASDAQ:SGMOBioCryst PharmaceuticalsNASDAQ:BCRXVoyager TherapeuticsNASDAQ:VYGRFate TherapeuticsNASDAQ:FATEView All CompetitorsInsiders & InstitutionsPutnam Investments LLCSold 13,890 shares on 5/22/2023Ownership: 0.094%JPMorgan Chase & Co.Bought 60,318 shares on 5/18/2023Ownership: 0.069%New York State Common Retirement FundSold 57,265 shares on 5/18/2023Ownership: 0.038%Susquehanna International Group LLPBought 120,200 shares on 5/16/2023Ownership: 0.000%AQR Capital Management LLCSold 66,918 shares on 5/16/2023Ownership: 0.031%View All Insider TransactionsView All Institutional Transactions AGEN Stock - Frequently Asked Questions Should I buy or sell Agenus stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agenus in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AGEN shares. View AGEN analyst ratings or view top-rated stocks. What is Agenus' stock price forecast for 2023? 4 Wall Street analysts have issued 1 year price targets for Agenus' stock. Their AGEN share price forecasts range from $5.00 to $8.30. On average, they predict the company's share price to reach $7.33 in the next twelve months. This suggests a possible upside of 359.2% from the stock's current price. View analysts price targets for AGEN or view top-rated stocks among Wall Street analysts. How have AGEN shares performed in 2023? Agenus' stock was trading at $2.40 on January 1st, 2023. Since then, AGEN stock has decreased by 33.5% and is now trading at $1.5950. View the best growth stocks for 2023 here. When is Agenus' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023. View our AGEN earnings forecast. How were Agenus' earnings last quarter? Agenus Inc. (NASDAQ:AGEN) released its quarterly earnings data on Tuesday, March, 14th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by $0.02. The biotechnology company had revenue of $28.39 million for the quarter, compared to analyst estimates of $17.83 million. Agenus had a negative net margin of 264.19% and a negative trailing twelve-month return on equity of 1,159.04%. What ETFs hold Agenus' stock? ETFs with the largest weight of Agenus (NASDAQ:AGEN) stock in their portfolio include Loncar Cancer Immunotherapy ETF (CNCR), WisdomTree BioRevolution Fund (WDNA), Virtus LifeSci Biotech Clinical Trials ETF (BBC), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Invesco Nasdaq Future Gen 200 ETF (QQQS), ALPS Medical Breakthroughs ETF (SBIO) and Principal Healthcare Innovators ETF (BTEC). What is Garo H. Armen's approval rating as Agenus' CEO? 2 employees have rated Agenus Chief Executive Officer Garo H. Armen on Glassdoor.com. Garo H. Armen has an approval rating of 56% among the company's employees. This puts Garo H. Armen in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Agenus own? Based on aggregate information from My MarketBeat watchlists, some companies that other Agenus investors own include (ROSG) (ROSG), Exelixis (EXEL), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), OPKO Health (OPK), Inovio Pharmaceuticals (INO), ADMA Biologics (ADMA), Gilead Sciences (GILD), Matinas BioPharma (MTNB) and RedHill Biopharma (RDHL). What is Agenus' stock symbol? Agenus trades on the NASDAQ under the ticker symbol "AGEN." Who are Agenus' major shareholders? Agenus' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include State Street Corp (7.50%), BlackRock Inc. (7.05%), Bank of America Corp DE (2.40%), Geode Capital Management LLC (1.58%), Renaissance Technologies LLC (1.34%) and Charles Schwab Investment Management Inc. (0.64%). Insiders that own company stock include Agenus Inc, Christine M Klaskin, Corp Incyte, Garo H Armen and Steven J O'day. View institutional ownership trends. How do I buy shares of Agenus? Shares of AGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Agenus' stock price today? One share of AGEN stock can currently be purchased for approximately $1.60. How much money does Agenus make? Agenus (NASDAQ:AGEN) has a market capitalization of $556.46 million and generates $98.02 million in revenue each year. The biotechnology company earns $-220,070,000.00 in net income (profit) each year or ($0.82) on an earnings per share basis. How many employees does Agenus have? The company employs 441 workers across the globe. How can I contact Agenus? Agenus' mailing address is 3 FORBES ROAD, LEXINGTON MA, 02421. The official website for the company is agenusbio.com. The biotechnology company can be reached via phone at (781) 674-4400, via email at investor@agenusbio.com, or via fax at 781-674-4200. This page (NASDAQ:AGEN) was last updated on 6/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Agenus Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.